These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12700444)

  • 1. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
    Parkin NT; Chappey C; Petropoulos CJ
    AIDS; 2003 May; 17(7):955-61. PubMed ID: 12700444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
    de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
    AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
    King MS; Rode R; Cohen-Codar I; Calvez V; Marcelin AG; Hanna GJ; Kempf DJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3067-74. PubMed ID: 17576846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    Hasson H; Gianotti N; Danise A; Seminari E; Boeri E; Nozza S; Castagna A; Lazzarin A
    AIDS; 2004 Jan; 18(1):123-7. PubMed ID: 15090838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
    Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
    AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
    Scudeller L; Torti C; Quiros-Roldan E; Patroni A; Lo Caputo S; Moretti F; Mazzotta F; Donati E; Vivarelli A; Carosi G;
    J Antimicrob Chemother; 2003 Nov; 52(5):776-81. PubMed ID: 14563897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Xu Y; Real K; Bernstein BM; Japour AJ; Sun E; Rode RA
    J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
    Valer L; González de Requena D; de Mendoza C; Martin-Carbonero L; González-Lahoz J; Soriano V
    AIDS Patient Care STDS; 2004 Jan; 18(1):1-6. PubMed ID: 15006188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
    Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
    J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
    Delaugerre C; Flandre P; Chaix ML; Ghosn J; Raffi F; Dellamonica P; Jaeger H; Shürmann D; Cohen-Codar I; Van PN; Norton M; Taburet AM; Delfraissy JF; Rouzioux C;
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2934-9. PubMed ID: 19451297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
    Parkin N; Chappey C; Maroldo L; Bates M; Hellmann NS; Petropoulos CJ
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):128-36. PubMed ID: 12394790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
    Paulsen D; Elston R; Snowden W; Tisdale M; Ross L
    J Antimicrob Chemother; 2003 Sep; 52(3):319-23. PubMed ID: 12917233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.